On June 30, 2026, the U.S. Food and Drug Administration authorized 20 specific ZYN nicotine pouch products to be marketed with a modified-risk claim.
The authorized claim states that using ZYN instead of cigarettes puts users at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis.
This is a notable moment for the nicotine pouch category - but it is also important to understand exactly what the FDA did and what it did not do.
What did the FDA authorize?
The FDA issued modified risk granted orders to Swedish Match USA, Inc. for 20 specific ZYN nicotine pouch products.
These include 10 ZYN varieties, each in two nicotine strengths: 3 mg and 6 mg. The products had already been authorized for sale in the United States through the FDA’s premarket tobacco product application pathway in January 2025.
The new authorization allows these specific products to be marketed with a specific modified-risk claim related to using ZYN instead of cigarettes.
This does not mean the same claim automatically applies to every nicotine pouch brand or to the entire category. The FDA states that modified-risk tobacco product orders apply to specific products, not a whole class of products.
Why does this matter?
For adults who smoke, conversations around nicotine are changing.
Cigarettes are strongly associated with serious health risks, many of which are linked to the toxic chemicals produced when tobacco is burned. Smoke-free nicotine products, including nicotine pouches, do not involve combustion. That difference is one reason nicotine pouches are increasingly part of harm-reduction discussions for adult smokers who are looking for alternatives to cigarettes.
The FDA’s decision does not mean nicotine pouches are risk-free. Nicotine is addictive, and nicotine products are not intended for minors, non-users, or people who do not already use nicotine.
However, the decision shows that regulators are willing to recognize meaningful differences between product types when a specific product and claim are supported by scientific evidence.
What this does not mean
This decision should not be misunderstood.
It does not mean nicotine pouches are “safe.”
It does not mean non-users should start using nicotine.
It does not mean all nicotine pouch brands can use the same claim.
It does not mean the FDA has authorized modified-risk claims for DIZZ products.
It does not mean the same rules automatically apply outside the United States.
The authorization applies only to the specific ZYN products and the specific claim reviewed by the FDA.
The FDA also states that there is no safe tobacco product and that adults who smoke would benefit most from fully quitting all tobacco and nicotine products. For those who do not quit, switching completely from cigarettes to FDA-authorized nicotine pouches may reduce exposure to many harmful chemicals found in cigarettes.
A step forward for clearer nicotine conversations
At DIZZ, we believe adult consumers deserve clear, honest and responsible information about nicotine products.
The FDA’s decision is important because it supports a more nuanced conversation: not all nicotine products are the same and adult users should have access to accurate information when making choices.
Nicotine pouches are adult-only products. They should never be marketed to minors or non-users. As the category continues to grow, responsible communication, clear standards and age-restricted access matter more than ever.
For brands, retailers and adult consumers, this is a development worth paying attention to.
Final thoughts
The FDA’s authorization of a modified-risk claim for specific ZYN nicotine pouch products marks an important regulatory moment.
It does not make broad claims possible for every brand. It does not make nicotine risk-free. But it does show that science-based communication and harm-reduction discussions are becoming more central to the future of nicotine products.
At DIZZ, we see this as a reminder that the category needs transparency, responsibility and adult-focused education - not vague claims or exaggerated promises.
Disclaimer
This article is for informational purposes only. DIZZ products have not been authorized by the U.S. Food and Drug Administration to make modified-risk claims. Nicotine is addictive and intended only for adults who already use nicotine products.
Sources
U.S. Food and Drug Administration. “FDA Authorizes 20 ZYN Nicotine Pouches to Be Marketed with Specific Modified Risk Claim.” Published June 30, 2026.
CNBC. “FDA allows Zyn nicotine pouches to say they may pose lower risk than cigarettes.” Published June 30, 2026.